Open Access Articles- Top Results for Teniposide


Systematic (IUPAC) name
Clinical data
AHFS/ monograph
MedlinePlus a692045
  • AU: D
  • US: D (Evidence of risk)
Pharmacokinetic data
Bioavailability n/a
Protein binding >99%
Metabolism Hepatic (CYP2C19-mediated)
Half-life 5 hours
Excretion Renal and fecal
29767-20-2 7pxY
PubChem CID 34698
DrugBank DB00444 7pxN
ChemSpider 31930 7pxN
UNII 957E6438QA 7pxN
KEGG D02698 7pxY
ChEBI CHEBI:75988 7pxN
ChEMBL CHEMBL1200536 7pxN
Chemical data
Formula C32H32O13S
656.655 g/mol
 14pxN (what is this?)  (verify)

Teniposide (Vumon, VM-26) is a chemotherapeutic medication[1] mainly used in the treatment of childhood acute lymphocytic leukemia (ALL). It is in a class of drugs known as podophyllotoxin derivatives and slows the growth of cancer cells in the body.

Mechanism of action

Teniposide causes dose-dependent single- and double-stranded breaks in DNA and DNA-protein cross-links. The mechanism of action appears to be related to the inhibition of type II topoisomerase activity since teniposide does not intercalate into DNA or bind strongly to DNA. The cytotoxic effects of teniposide are related to the relative number of double-stranded DNA breaks produced in cells, which are a reflection of the stabilization of a topoisomerase II-DNA intermediate.


The medication is injected though a vein and burns if it leaks under the skin. It is sometimes used in combination with other anticancer drugs.


Teniposide, when used with other chemotherapeutic agents for the treatment of ALL, results in severe myelosuppression. Other common side effects include gastrointestinal toxicity, hypersensitivity reactions, and alopecia.


  1. ^ Cragg, Gordon M.; Newman, David J. (2005). "Plants as a source of anti-cancer agents". Journal of Ethnopharmacology 100 (1–2): 72–9. PMID 16009521. doi:10.1016/j.jep.2005.05.011. 

Lua error in package.lua at line 80: module 'Module:Buffer' not found.